AbstractOsteoarthritis (OA) remains one of the greatest healthcare burdens in western society, with chronic debilitating pain-dominating clinical presentation yet therapeutic strategies are inadequate in many patients. Development of better analgesics is contingent on improved understanding of the molecular mechanisms mediating OA pain. Voltage-gated calcium channels 2.2 (Cav2.2) play a critical role in spinal nociceptive transmission, therefore blocking Cav2.2 activity represents an attractive opportunity for OA pain treatment, but the only available licensed Cav2.2 antagonist ziconitide (PrilatTM) is of limited use. TROX-1 is an orally available, use dependent and state-selective Cav2 antagonist, exerting its analgesic effect primarily vi...
AbstractAlthough T-type calcium channels were first described in sensory neurons, their function in ...
Background: Harnessing the actions of the resolvin pathways has the potential for the treatment of a...
Osteoarthritis (OA), a chronic degenerative joint disease, will affect an increasing number of indiv...
AbstractPrialt, a synthetic version of Cav2.2 antagonist ω-conotoxin MVIIA derived from Conus magus,...
AbstractVoltage-gated sodium channel blockers are not traditionally recommended for osteoarthritis (...
Abstract Background Peripheral and central nociceptive sensitization is a critical pathogenetic comp...
SummaryObjectiveEvidence suggests that osteoarthritis (OA) is associated with altered central pain p...
The mechanisms underlying the transition from acute nociceptive pain to centrally maintained chronic...
OBJECTIVE: Pain is the main reason patients report Osteoarthritis (OA), yet current analgesics remai...
Osteoarthritis (OA) is expected to become the fourth leading cause of disability worldwide by 2020. ...
SummaryObjectiveOsteoarthritis (OA) is a complex and painful disease of the whole joint. At present ...
Osteoarthritis (OA) is the most common form of arthritis, with chronic pain being the most frequent ...
Objectives Blockade of transient receptor potential vanilloid 1 (TRPV1) with systemic antagonists at...
Neuropathic pain remains poorly treated for large numbers of patients and little progress has been m...
Objective: A hallmark of rheumatoid arthritis (RA) is the chronic pain that accompanies the inflamma...
AbstractAlthough T-type calcium channels were first described in sensory neurons, their function in ...
Background: Harnessing the actions of the resolvin pathways has the potential for the treatment of a...
Osteoarthritis (OA), a chronic degenerative joint disease, will affect an increasing number of indiv...
AbstractPrialt, a synthetic version of Cav2.2 antagonist ω-conotoxin MVIIA derived from Conus magus,...
AbstractVoltage-gated sodium channel blockers are not traditionally recommended for osteoarthritis (...
Abstract Background Peripheral and central nociceptive sensitization is a critical pathogenetic comp...
SummaryObjectiveEvidence suggests that osteoarthritis (OA) is associated with altered central pain p...
The mechanisms underlying the transition from acute nociceptive pain to centrally maintained chronic...
OBJECTIVE: Pain is the main reason patients report Osteoarthritis (OA), yet current analgesics remai...
Osteoarthritis (OA) is expected to become the fourth leading cause of disability worldwide by 2020. ...
SummaryObjectiveOsteoarthritis (OA) is a complex and painful disease of the whole joint. At present ...
Osteoarthritis (OA) is the most common form of arthritis, with chronic pain being the most frequent ...
Objectives Blockade of transient receptor potential vanilloid 1 (TRPV1) with systemic antagonists at...
Neuropathic pain remains poorly treated for large numbers of patients and little progress has been m...
Objective: A hallmark of rheumatoid arthritis (RA) is the chronic pain that accompanies the inflamma...
AbstractAlthough T-type calcium channels were first described in sensory neurons, their function in ...
Background: Harnessing the actions of the resolvin pathways has the potential for the treatment of a...
Osteoarthritis (OA), a chronic degenerative joint disease, will affect an increasing number of indiv...